Therma Bright receives order for 200 Venowave VW5 units

Executive Summary

• Therma Bright Inc. has secured a follow-on order for 200 Venowave VW5 units from its strategic distribution partner, Gen-X Med, marking an expansion of their commercial relationship.
• The units are designated for use by top-tier orthopedic surgeons in the U.S. to support postsurgical recovery for specialized knee procedures, targeting a high-growth segment of the healthcare market.
• Management highlights strong clinical demand and reimbursement advantages, noting the device is the only Medicare-approved reimbursable mobile mechanical compression system in the U.S. under HCPCS code E0683.

Key Details

• Transaction Volume: Additional order for 200 Venowave VW5 units.
• Counterparty: Gen-X Med, a Texas-based distribution partner.
• Product Application: Targeted at orthopedic surgeons for postsurgical recovery in specialized knee procedures.
• Market Context: The global compression therapy market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033 (CAGR of 7.30%).
• Device Specifications: The Venowave VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for circulatory disorders.
• Clinical Efficacy: Clinically shown to enhance venous blood flow by 64% after two minutes of use and 88% after 50 minutes.
• Regulatory Status: FDA-designated durable medical equipment (DME); the only Medicare-approved reimbursable mobile mechanical compression system in the U.S. under HCPCS code E0683.

Notable Quotes

• Rob Fia, CEO of Therma Bright: "The speed at which Gen-X Med has returned for additional inventory speaks volumes about the clinical demand for the Venowave VW5. This second 200-unit order reinforces our belief that the market is hungry for mobile, effective and reimbursable compression solutions."
• Beau Wood, President of Gen-X Med: "Our initial rollout confirmed what we suspected: Patients and providers prefer the mobility and efficacy of the Venowave over traditional, tethered compression devices. Securing these additional 200 units allows us to keep pace with the growing adoption rate among our specialized knee surgeons."